Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant human thrombopoietin clinical development.

D V Jones1, M Ashby, S Vadhan-Raj

  • 1Genentech, Inc., South San Francisco, California, USA.

Stem Cells (Dayton, Ohio)
|September 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

3D TOF-PET image reconstruction using total variation regularization.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2020
Same author

Performance assessment of the 2 γpositronium imaging with the total-body PET scanners.

EJNMMI physics·2020
Same author

Estimating relationship between the time over threshold and energy loss by photons in plastic scintillators used in the J-PET scanner.

EJNMMI physics·2020
Same author

Evaluation of a surgical training programme for clinical officers in Malawi.

The British journal of surgery·2019
Same author

'I think we are going to leave these cases'. Obstacles to surgery in rural Malawi: a qualitative study of provider perspectives.

Tropical medicine & international health : TM & IH·2018
Same author

Reticulocyte and erythrocyte hypochromia markers in detection of iron deficiency in adolescent female athletes.

Biology of sport·2017

Recombinant human thrombopoietin (rHuTPO) shows promise in managing chemotherapy-induced thrombocytopenia. This therapy may reduce bleeding risks and allow for consistent anticancer treatment delivery.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Anticancer therapies frequently cause thrombocytopenia, increasing bleeding risk and necessitating dose reductions.
  • Current treatment involves platelet transfusions, which carry risks of alloimmunization and infection.
  • Effective interventions for thrombocytopenia are crucial for maintaining optimal cancer treatment intensity.

Purpose of the Study:

  • To evaluate the safety and efficacy of recombinant human thrombopoietin (rHuTPO) in patients undergoing chemotherapy.
  • To assess rHuTPO's potential to mitigate chemotherapy-induced thrombocytopenia and its associated complications.

Main Methods:

  • Phase 1 clinical trials investigating rHuTPO in patients receiving myelosuppressive or myeloablative therapy.
  • Specific trials include rHuTPO in women with gynecologic malignancies and for progenitor cell mobilization in breast cancer patients.

Related Experiment Videos

Main Results:

  • Preliminary data from ongoing phase 1 trials will be presented.
  • The data will illustrate the safety and activity of rHuTPO in relevant patient populations.

Conclusions:

  • rHuTPO is a potential therapeutic agent for managing chemotherapy-induced thrombocytopenia.
  • Further studies are warranted to establish rHuTPO's role in supportive cancer care.